IMCCHealthcare · Drug Manufacturers - Specialty & GenericTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 1 Aug 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores IM Cannabis Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (100): Smaller than most of the companies we track.
Momentum (1): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own IM Cannabis Corp. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on IMCC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 Dec 2021 | Roth Capital | Initiates | Buy | — |
| 5 Oct 2021 | Roth Capital | Initiates | Buy | — |
| 10 June 2021 | Alliance Global Partners | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 76% of US stocks
Cheaper than 99% of US stocks
Cheaper than 93% of US stocks
Cheaper than 73% of US stocks
Higher than 8% of US stocks
Higher than 15% of US stocks
Higher than 17% of US stocks
Higher than 23% of US stocks
Higher than 14% of US stocks
Higher than 99% of US stocks
Higher than 23% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IMCC appears on the weeks it earns a place.
IM Cannabis Corp. announced that director Alon Dayan has resigned from the board for personal reasons.
Why it matters — A board member's resignation could signal a shift in corporate governance or leadership dynamics at the company.
Of the 1 analysts covering IM Cannabis Corp., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks IM Cannabis Corp. 23 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, IM Cannabis Corp. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (100 of 100).
No analyst covering IM Cannabis Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMCC are extrapolating price history, which says nothing about the business.
IM Cannabis Corp. returned -95.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Im Cannabis Corp. is a globally recognized player in the cannabis industry, specializing in the cultivation, processing, and distribution of medical and recreational cannabis products.
The most recent item we track (PRNewsWire, 27 July 2026): "IM Cannabis Provides Corporate Update". IM Cannabis Corp. announced that director Alon Dayan has resigned from the board for personal reasons.
Im Cannabis Corp. is a globally recognized player in the cannabis industry, specializing in the cultivation, processing, and distribution of medical and recreational cannabis products. With operations particularly focused in Israel, Canada, and Germany, the company leverages its multi-national presence to drive innovation in cannabis research and development. Im Cannabis Corp. plays a pivotal role in advancing cannabis as a viable pharmaceutical alternative, working alongside health professionals to improve patient care. The firm is deeply involved in scientific studies and the development of new strains, aiming to enhance the efficacy and safety of cannabis products. As the industry experiences rapid growth and increasing regulatory acceptance worldwide, Im Cannabis Corp. is positioned at the forefront of this evolution, contributing to the expansion and quality assurance of cannabis offerings across different markets. Its strategic partnerships and comprehensive supply chain management underscore its commitment to leadership in this burgeoning sector.
CEO Mr. Oren Shuster · 44 employees · Canada · https://imcannabis.com